drugset / Trial / NCT01174238

A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma

NCT01174238

Phase 2 Completed 40 enrolled Adil Daud
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a two arm prospective Phase II pilot trial designed to determine the optimal duration of break between axitinib and chemotherapy with carboplatin/paclitaxel in melanoma. In this study, 6 patients will be enrolled to Arm A, the FLT PET scan (3'deoxy-3'-18F-Fluorothymidine positron emission tomography scans)cohort. 30 patients will be enrolled to Arm B, the treatment-only cohort. 36 total patients will be enrolled. The treatment schedule will be the same in either cohort, with the exception of the FLT PET scans.

Timeline

Start
2010-07
Primary completion
2013-08
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg Oral
Subject Carboplatin Small molecule 5 unknown
Subject Paclitaxel Small molecule 175 mg/m2

Indications